PIK-108

PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1].

Research Areas >> Cancer

Signaling Pathways >> PI3K/Akt/mTOR >> PI3K

PIK-108 (0.1-10 μM; 1 hour) blocks phosphorylation of PKB/Akt[1]. Western Blot Analysis[1] Cell Line: Glioma cell lines expressing wild-type PTEN Concentration: 0.1, 0.5, 1, 4, and 10 μM Incubation Time: 1 hour Result: Showed variable inhibition of PKB/Akt phosphorylation but exhibited a trend toward reducing PKB/Akt phosphorylation more effectively in mutant PTEN-expressing cell lines than in wild-type PTEN-expressing cell lines.

[1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.

[2]. Jack S Chen, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008 Apr;7(4):841-50.